Choice of Anticoagulant for Primary Hemostasis Studies with PFA200® (Platelet Function Analyser)

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DIJON · Dec 23, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how different types of blood anticoagulants affect a specific blood test called the PFA (Platelet Function Analyser) test, which helps doctors understand how well your blood can form clots. The researchers want to compare the results from using a regular anticoagulant called citrate with another type called BAPA, which is thought to impact the blood platelets less. This comparison will help determine if one type of anticoagulant is better for accurate testing.

To be eligible for this trial, participants must be adults who have agreed to take part and are receiving care for bleeding disorders at a specialized clinic. They should also be having a PFA test done as part of their regular medical care; this test will not be added just for the study. However, individuals under legal protection, pregnant or breastfeeding women, and those unable to give consent cannot participate. If you join the study, you'll simply have your blood drawn during your regular visit, and the study team will handle the rest. Your participation could help improve how these tests are done in the future!

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Person having given their non-opposition
• • Person of legal age
• • Person receiving a haemostasis consultation at the haemophilia and haemorrhagic diseases treatment center followed by a blood sample with a PFA test prescribed by the doctor (the test is not added for the study).
• Exclusion Criteria:
• • persons under legal protection (curatorship, guardianship)
• • persons subject to a court protection order
• • pregnant, parturient or breast-feeding women
• • adult incapable or unable to give consent
• • minor